Business Context and Reporting Period
This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on January 10, 2020. The filing provides preliminary, unaudited financial results for the quarter and fiscal year ended December 31, 2019. The Company is an emerging growth company listed on the Nasdaq Capital Market under the symbol EKSO.
Key Financial Metrics
- Q4 2019 Revenue: Estimated at $3.7 million, comprising approximately $3.2 million in medical revenue and $0.5 million in industrial product shipments.
- Fiscal Year 2019 Revenue: Estimated at $13.9 million.
- Cash Position: Estimated cash on hand as of December 31, 2019, is $10.9 million.
- Profit, Margins, and Debt: The filing text does not provide clear values for net income, profit margins, or specific debt obligations.
Material Changes vs. Prior Period
- Q4 Revenue Growth: Q4 2019 revenue increased by 12.1% year-over-year compared to $3.3 million in Q4 2018.
- Full Year Revenue Growth: Fiscal 2019 revenue increased by 23.0% year-over-year compared to $11.3 million in 2018.
- Liquidity Improvement: Cash on hand increased by approximately $3.2 million, rising from $7.7 million as of December 31, 2018, to $10.9 million as of December 31, 2019.
Outlook, Risks, and Unusual Items
The financial data presented is based on management's preliminary unaudited analysis. The Company has not completed its financial statement reporting process, and the independent registered accounting firm has not audited these figures. Consequently, the results are subject to potential material adjustments during the final closing procedures. The filing explicitly states that these estimates constitute forward-looking information and are not guarantees of actual results. No specific guidance for future periods or detailed risk factors beyond standard forward-looking statement disclaimers are provided in this text.
Investor Verification Checklist
- Verify the final audited financial statements for Q4 and FY 2019 to confirm if the preliminary revenue and cash estimates hold.
- Review the attached Press Release (Exhibit 99.1) for additional context on the breakdown of medical versus industrial revenue.
- Monitor subsequent filings for any material adjustments to the preliminary data disclosed in this 8-K.
- Confirm the Company's cash burn rate and runway, as only the cash balance is disclosed without operating expense details.